ProCE Banner Activity

CME

Innovative Therapeutic Approaches for Immune Thrombocytopenia

Multimedia
In this interactive recording of a live CCO webinar, experts discuss promising novel therapeutic strategies for treating patients with ITP beyond the current standards of care.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 05, 2021

Expiration: August 04, 2022

No longer available for credit.

Share

Faculty

Catherine M. Broome

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

David J. Kuter

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

UCB Biopharma SRL

Target Audience

This program is intended for global physicians and other healthcare professionals who care for patients with ITP.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe recent advances in the understanding of immune thrombocytopenia pathophysiology that have led to the development of new targeted therapies
  • Identify the mechanism of action of novel targeted therapies that are being tested for patients with immune thrombocytopenia
  • Evaluate the available efficacy and safety data for novel targeted therapies in patients with immune thrombocytopenia
  • Discuss ongoing clinical trials investigating novel targeted therapies and combination regimens for the treatment of immune thrombocytopenia

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

Catherine M. Broome, MD, has disclosed that she has received fees for non-CME/CE services from Alexion, Appelis, Argenx, and Sanofi.

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

David J. Kuter, MD, DPhil, has disclosed that he has received funds for research support from Actelion (Syntimmune), Agios, Alnylam, Amgen, Argenx, Bristol-Myers Squibb, Immunovant, Kezar, Principia, Protalex, Rigel, Takeda (Bioverativ), and UCB and consulting fees from Actelion (Syntimmune), Agios, Alnylam, Amgen, Argenx, BioCryst, Bristol-Myers Squibb, Daiicho Sankyo, Dova, Genzyme, Immunovant, Incyte, Kyowa Kirin, Merck, Momenta, Novartis, Pfizer, Principa, Protalex, Protalix, Rigel, Sanofi Genzyme, Shionogi, Shire, Takeda (Bioverativ), UCB, and Zafgen.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 05, 2021, through August 04, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners to integrate emerging and innovative therapies for ITP.